Cetuximab [205923-56-4]
Référence T9905-2mg
Conditionnement : 2mg
Marque : TargetMol
Cetuximab (Synonyms: Cetuximab (anti-EGFR), C225)
Cetuximab
Copy Product InfoSynonyms Cetuximab (anti-EGFR), C225
Cas No. 205923-56-4
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:98.60%
Appearance:Liquid
Color:Transparent
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis. |
| Targets&IC50 | EGFR:0.201 nM (Kd), HCT116 cells:358.0 µg/mL, EGFR:0.147 nM (Kd, Fixed A431 cells), SW48 cells:262.4 µg/mL, GEO-CR cells:27.7 nM |
| In vitro | METHODS: Human squamous cell carcinoma (SCC) cells SCC-13Y, SCC-38, SCC-1, and SCC-11B were treated with Cetuximab (30 nM) for 8 days, and cell numbers were measured using a hemacytometer. RESULTS: Cetuximab inhibited cell proliferation of SCC cells in a time-dependent manner. Cetuximab inhibited the growth of SCC cell lines in a time-dependent manner, ranging from 20%-75% compared to untreated controls. [1] METHODS: EGFR mutant cells PC-9 and EGFR wild-type cells PC-14, A549 were treated with Cetuximab (10-100 µg/mL) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: EGFR phosphorylation was strongly expressed in PC-9 and continued to be strongly expressed during Cetuximab treatment.In PC-14 and A549 cells, although the increase in EGFR phosphorylation was reduced by the addition of Cetuximab, phosphorylation was not completely inhibited at the highest concentration. [2] |
| In vivo | METHODS: To assay antitumor activity in vivo, Cetuximab (1 mg/injection) was administered intraperitoneally to BALB/c (nu/nu) mice harboring HNSCC tumors UT-SCC-2 or UT-SCC-14 on the 10th, 13th, and 16th days after tumor cell injection. RESULTS: Cetuximab treatment reduced tumor growth in HNSCC xenografts and increased local oxygen partial pressure in tumors. [3] METHODS: To study in vivo antitumor activity, Cetuximab (0.25-1 mg/mouse) was administered intraperitoneally to nude mice bearing xenograft tumors every three days for a minimum of five injections. RESULTS: Treatment with Cetuximab alone effectively delayed the growth of GEO and L2987 tumors for at least 10 days. Borderline activity was observed in A549 and WiDr xenografts. However, Cetuximab did not show any significant anti-tumor activity in HT29, HCT116, LOVO, Colo205, LX-1, HCC70 and N87 models. [4] |
| Synonyms | Cetuximab (anti-EGFR), C225 |
| Reactivity | Human |
| Verified Activity | Immobilized Human EGFR Protein (ECD, His) (TMPY-00742) at 1 μg/mL can bind Cetuximab. The EC50 is 1.45 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | 1956 |
| Uniprot ID | P00533 |
| Target | ERBB1/EGFR/HER1 |
| Molecular Weight | 145.54 kDa |
| Cas No. | 205923-56-4 |
| Relative Density. | no data available |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control | Human IgG1 kappa, Isotype Control |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |